231 related articles for article (PubMed ID: 21723096)
1. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.
Gottlieb JD; Cather C; Shanahan M; Creedon T; Macklin EA; Goff DC
Schizophr Res; 2011 Sep; 131(1-3):69-74. PubMed ID: 21723096
[TBL] [Abstract][Full Text] [Related]
2. D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial.
Diminich ED; Dickerson F; Bello I; Cather C; Kingdon D; Rakhshan Rouhakhtar PJ; Hart KL; Li C; Troxel AB; Goff DC
Schizophr Res; 2020 Aug; 222():145-152. PubMed ID: 32591238
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
[TBL] [Abstract][Full Text] [Related]
4. Effects of cognitive behaviour therapy for worry on persecutory delusions in patients with psychosis (WIT): a parallel, single-blind, randomised controlled trial with a mediation analysis.
Freeman D; Dunn G; Startup H; Pugh K; Cordwell J; Mander H; Černis E; Wingham G; Shirvell K; Kingdon D
Lancet Psychiatry; 2015 Apr; 2(4):305-13. PubMed ID: 26360083
[TBL] [Abstract][Full Text] [Related]
5. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population.
Kennedy AP; Gross RE; Whitfield N; Drexler KP; Kilts CD
Addict Behav; 2012 Aug; 37(8):900-7. PubMed ID: 22578380
[TBL] [Abstract][Full Text] [Related]
7. d-Cycloserine augmentation of cognitive remediation in schizophrenia.
Cain CK; McCue M; Bello I; Creedon T; Tang DI; Laska E; Goff DC
Schizophr Res; 2014 Mar; 153(1-3):177-83. PubMed ID: 24485587
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress.
Scheeringa MS; Weems CF
J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):69-77. PubMed ID: 24506079
[TBL] [Abstract][Full Text] [Related]
9. Does Change over Time in Delusional Beliefs as Measured with PDI Predict Change over Time in Belief Flexibility Measured with MADS?
Penzenstadler L; Chatton A; Huguelet P; Lecardeur L; Bartolomei J; Brazo P; Murys E; Poupart F; Rouvière S; Saoud M; Favrod J; Khazaal Y
Psychiatr Q; 2019 Dec; 90(4):693-702. PubMed ID: 31338790
[TBL] [Abstract][Full Text] [Related]
10. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder.
Hofmann SG; Smits JA; Rosenfield D; Simon N; Otto MW; Meuret AE; Marques L; Fang A; Tart C; Pollack MH
Am J Psychiatry; 2013 Jul; 170(7):751-8. PubMed ID: 23599046
[TBL] [Abstract][Full Text] [Related]
11. Thinking Well: A randomised controlled feasibility study of a new CBT therapy targeting reasoning biases in people with distressing persecutory delusional beliefs.
Waller H; Emsley R; Freeman D; Bebbington P; Dunn G; Fowler D; Hardy A; Kuipers E; Garety P
J Behav Ther Exp Psychiatry; 2015 Sep; 48():82-9. PubMed ID: 25770671
[TBL] [Abstract][Full Text] [Related]
12. D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update.
Hofmann SG; Otto MW; Pollack MH; Smits JA
Curr Psychiatry Rep; 2015 Jan; 17(1):532. PubMed ID: 25413638
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.
Otto MW; Tolin DF; Simon NM; Pearlson GD; Basden S; Meunier SA; Hofmann SG; Eisenmenger K; Krystal JH; Pollack MH
Biol Psychiatry; 2010 Feb; 67(4):365-70. PubMed ID: 19811776
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
15. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
16. The Therapeutic Role of d-Cycloserine in Schizophrenia.
Goff D
Adv Pharmacol; 2016; 76():39-66. PubMed ID: 27288073
[TBL] [Abstract][Full Text] [Related]
17. Targeting reasoning biases in delusions: a pilot study of the Maudsley Review Training Programme for individuals with persistent, high conviction delusions.
Waller H; Freeman D; Jolley S; Dunn G; Garety P
J Behav Ther Exp Psychiatry; 2011 Sep; 42(3):414-21. PubMed ID: 21481815
[TBL] [Abstract][Full Text] [Related]
18. Individualized Metacognitive Training (MCT+) Reduces Delusional Symptoms in Psychosis: A Randomized Clinical Trial.
Balzan RP; Mattiske JK; Delfabbro P; Liu D; Galletly C
Schizophr Bull; 2019 Jan; 45(1):27-36. PubMed ID: 30376124
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
20. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.
Urbano M; Okwara L; Manser P; Hartmann K; Herndon A; Deutsch SI
Clin Neuropharmacol; 2014; 37(3):69-72. PubMed ID: 24824660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
